Study results, published in Diabetes Technology and Therapeutics, demonstrate clinically significant improved glycemic control in people with diabetes using a smart meter and mobile app

Malvern, Pa., November 7, 2022 /PRNewswire/ — LifeScan, a global leader in blood glucose monitoring, announced today that the peer-reviewed journal Diabetes Technology and Therapeutics (DTT) published Real World Evidence of Improved Glycemic Control in Diabetics Using a Bluetooth® connected Blood Glucose has published a meter with a mobile diabetes management application that describes the results of a retrospective analysis of real-world data from more than 17,000 people with diabetes. A subset of these results were first presented at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in April.

Using real-world data, this study sought to understand whether using the OneTouch Reveal® Mobile App with the OneTouch Verio Reflect® Glucose Meter—synced via Bluetooth® wireless technology—could support improved glycemic control for people with diabetes. The researchers examined anonymized blood glucose readings from over 17,000 people with diabetes from a LifeScan data lake that included 4,154 people with type 1 diabetes (T1D) and 13,623 people with type 2 diabetes (T2D).

“This new real-world evidence provides further reassurance that the latest app-connected blood glucose meters offer significant clinical benefits for people with type 1 or type 2 diabetes,” said Dr. Oliver SchnellFounder and Managing Director Sciarc GmbH, Germany. “In addition to improved glucose control, pairing glucose meters with apps also allows people with diabetes to easily and accurately share data and insights remotely or in person with their healthcare providers.”

Retrospective analysis found that using the OneTouch Reveal® App with the OneTouch Verio Reflect® Meter:

  • Improved glucose readings in the range (3.9-10.0 mmol/L) by +8.1% in T1Ds (37% of T1Ds saw an improvement of +10%) and by +11.2% in T2Ds;
  • Reduced hyperglycemic values ​​(>10.0 mmol/L) by -8.5% in T1Ds and -11.3% in T2Ds; and
  • Reduced mean glucose by -0.8 mmol/L in T1Ds and -1.0 mmol/L in T2Ds.

The data also showed that as little as 11 to 20 minutes per week on the OneTouch Reveal® app resulted in:

  • Improved area glucose readings in T1Ds by +8.4% and +11.8% in T2Ds; and
  • Reduced hyperglycemic readings (> 10.0 mmol/L) in T1Ds by -9.12% and -11.76% in T2Ds.

This analysis includes data from diabetic patients for whom blood glucose (BG) data was available for both the first 14 days using the OneTouch Verio Reflect® meter with the OneTouch Reveal® app (the baseline) and the 14 days prior to this in the data lake up to 90 days of usage (90 days). A total of 2,069,390 and 4,550,601 BG results were available for the 4,154 T1Ds and 13,623 T2Ds, respectively, over the full 90 days (cf TABLE).

“We now know that connecting a mobile health app with a blood glucose meter, both of which are easily accessible, can provide a clinically significant benefit for people’s diabetes management,” said study co-author Dr. Elizabeth Holt, Head of Global Medical, Clinical and Safety, LifeScan. “These results are particularly meaningful given that over 95% of people with diabetes who monitor their blood glucose rely on blood glucose meters rather than more expensive continuous glucose monitoring devices.”

study methodology

Anonymized glucose and App analyzes were extracted from a LifeScan data lake of 4,154 people with T1D and 13,623 people with T2D. Data from the first 14 days were compared to the 14 days prior to the 90 day time point using pairwise intra-subject differences.

TABLE

time in the app

(Per week)

≤2
protocol

3 to 5
protocol

6 to 10
protocol

11 to 20
protocol

21 to 60
protocol

>60
protocol

diabetes type

T1D
(n=

355)

T2D

(n=
849)

T1D
(n=
514)

T2D

(n=

1265)

T1D

(n=655)

T2D

(n=

1728)

T1D (n=
721)

T2D

(n=2439)

T1D

(n=

1107)

T2D

(n=

4701)

T1D
(n=

802)

T2D

(n=

2641)

Mean Glucose (mmol/L)

+0.0

-0.3

-0.1

-0.8

-0.3

-1.0

-0.8

-1.0

-0.5

-1.1

-1.6

-1.2

% read s

in the area

(3.9 to 10.0 mmol/L)

+0.16

+3.00

+2.98

+8.13

+3.45

+10.54

+8.45

+11.87

+11.03

+12.18

+14.13

+13.40

% Hyperglycemic readings

(>10.0 mmol/L)

+0.05

-3.12

-2.78

– 8.43

-3.48

-10.77

-9.12

-11.76

-11.51

-12.35

-15.33

-13.57

Average

test frequency

3.02

2:15

3:15

1.99

3:19

2.02

3.05

1.97

3.04

2.04

4.08

2.66

About LifeScan’s OneTouch® Brand
LifeScan is a global leader in blood glucose monitoring and digital health technology with a vision to create a world without borders for people living with diabetes and related conditions. More than 20 million people and their caregivers around the world rely on LifeScan’s OneTouch® brand products to manage their diabetes. Together, LifeScan and OneTouch improve the quality of life for people with diabetes with products and digital platforms built on simplicity, accuracy and trust. LifeScan.com and myOneTouch.co.uk.

The bluetooth® The word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by LifeScan Scotland Ltd. and its subsidiaries is under license.

Logo – https://mma.prnewswire.com/media/749088/Lifescan_Logo.jpg

SOURCE Lifescan, Inc.

source

Leave a Reply

Your email address will not be published. Required fields are marked *